Signos — Glucose monitoring app for weight management
Recently funded· $20M Series C· May 27, 2026
Signos makes an FDA-cleared, over-the-counter continuous glucose monitoring app that turns biosensor data into personalized insights for weight management. The California-based company pairs Dexcom CGM hardware with an AI engine that helps non-diabetic users link food, activity, and metabolic response, and is sold direct-to-consumer through Dexcom's Stelo channel.
Get it by email
Companies like Signos go out every weekday morning. One-click unsubscribe.
- Round
- $20M Series C
- Investors
- Gv, Blue Cross Blue Shield of Alabama, Dexcom Ventures
- Logged
- May 27, 2026
- Website
- www.signos.com
Investor
Gv also backed Blacksmith, Odyssey AI, Verse